End-of-day quote
Korea S.E.
06:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
33,550
KRW
|
-1.03%
|
|
+0.75%
|
-14.41%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
5,010,439
|
2,480,585
|
5,020,056
|
3,646,182
|
2,206,472
|
2,664,917
|
Enterprise Value (EV)
1 |
5,003,581
|
2,508,896
|
5,056,459
|
3,686,047
|
2,386,962
|
2,844,145
|
P/E ratio
|
278
x
|
80.7
x
|
222
x
|
84.9
x
|
32.1
x
|
23.1
x
|
Yield
|
0.25%
|
0.52%
|
0.26%
|
0.36%
|
0.62%
|
0.51%
|
Capitalization / Revenue
|
7.08
x
|
3.04
x
|
5.86
x
|
3.84
x
|
2.11
x
|
2.14
x
|
EV / Revenue
|
7.07
x
|
3.07
x
|
5.9
x
|
3.88
x
|
2.28
x
|
2.28
x
|
EV / EBITDA
|
321
x
|
111
x
|
161
x
|
108
x
|
71.1
x
|
43.3
x
|
EV / FCF
|
1,966
x
|
364
x
|
544
x
|
682
x
|
-132
x
|
62.5
x
|
FCF Yield
|
0.05%
|
0.27%
|
0.18%
|
0.15%
|
-0.76%
|
1.6%
|
Price to Book
|
7.52
x
|
3.84
x
|
7.62
x
|
5.28
x
|
3.04
x
|
3.37
x
|
Nbr of stocks (in thousands)
|
68,651
|
68,642
|
68,632
|
68,618
|
67,996
|
67,983
|
Reference price
2 |
72,984
|
36,138
|
73,145
|
53,137
|
32,450
|
39,200
|
Announcement Date
|
3/7/19
|
3/12/20
|
3/18/21
|
3/16/22
|
3/21/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
707,995
|
816,619
|
857,383
|
950,165
|
1,046,054
|
1,247,906
|
EBITDA
1 |
15,602
|
22,520
|
31,360
|
34,009
|
33,590
|
65,744
|
EBIT
1 |
10,997
|
16,145
|
25,152
|
28,753
|
28,112
|
57,012
|
Operating Margin
|
1.55%
|
1.98%
|
2.93%
|
3.03%
|
2.69%
|
4.57%
|
Earnings before Tax (EBT)
1 |
18,820
|
35,432
|
29,966
|
49,122
|
73,180
|
130,542
|
Net income
1 |
18,020
|
30,742
|
22,601
|
42,942
|
69,210
|
115,122
|
Net margin
|
2.55%
|
3.76%
|
2.64%
|
4.52%
|
6.62%
|
9.23%
|
EPS
2 |
262.8
|
447.9
|
329.3
|
625.8
|
1,010
|
1,694
|
Free Cash Flow
1 |
2,545
|
6,891
|
9,297
|
5,406
|
-18,030
|
45,486
|
FCF margin
|
0.36%
|
0.84%
|
1.08%
|
0.57%
|
-1.72%
|
3.64%
|
FCF Conversion (EBITDA)
|
16.31%
|
30.6%
|
29.65%
|
15.9%
|
-
|
69.19%
|
FCF Conversion (Net income)
|
14.12%
|
22.42%
|
41.14%
|
12.59%
|
-
|
39.51%
|
Dividend per Share
2 |
184.8
|
188.5
|
188.5
|
192.2
|
200.0
|
200.0
|
Announcement Date
|
3/7/19
|
3/12/20
|
3/18/21
|
3/16/22
|
3/21/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
28,311
|
36,403
|
39,865
|
180,489
|
179,228
|
Net Cash position
1 |
6,858
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.257
x
|
1.161
x
|
1.172
x
|
5.373
x
|
2.726
x
|
Free Cash Flow
1 |
2,545
|
6,891
|
9,297
|
5,406
|
-18,030
|
45,486
|
ROE (net income / shareholders' equity)
|
2.73%
|
4.73%
|
3.46%
|
6.37%
|
9.76%
|
15.1%
|
ROA (Net income/ Total Assets)
|
0.74%
|
1.1%
|
1.71%
|
1.92%
|
1.71%
|
3.05%
|
Assets
1 |
2,432,441
|
2,783,813
|
1,318,463
|
2,238,078
|
4,056,596
|
3,773,362
|
Book Value Per Share
2 |
9,703
|
9,407
|
9,598
|
10,060
|
10,659
|
11,621
|
Cash Flow per Share
2 |
399.0
|
244.0
|
216.0
|
242.0
|
315.0
|
407.0
|
Capex
1 |
770
|
1,253
|
958
|
1,816
|
7,398
|
6,930
|
Capex / Sales
|
0.11%
|
0.15%
|
0.11%
|
0.19%
|
0.71%
|
0.56%
|
Announcement Date
|
3/7/19
|
3/12/20
|
3/18/21
|
3/16/22
|
3/21/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -14.41% | 1.68B | | +19.98% | 43.67B | | +20.67% | 22.51B | | +14.56% | 14.6B | | +14.32% | 13.74B | | +44.72% | 11.91B | | -8.37% | 7.04B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +11.90% | 5.42B |
Generic Pharmaceuticals
|